📰 Genentech News
Page 112 - Genentech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Genentech. Real-time updates on events, politics, business and more.
August 23, 2023
Basel, 23 August 2023 - Roche announced today that it has been made aware of an inadvertent disclosure of the second interim analysis of the Phase III SKYSCRAPER-01 study, evaluating the...
August 23, 2023
Basel, 23 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has been made aware of an inadvertent disclosure of the second interim...
August 23, 2023
OSLO, Norway, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the...
August 23, 2023
T cell bispecific antibodies (TCBs) are an emerging class of immunotherapeutics with several TCBs approved by the FDA for the treatment of leukemias, lymphomas, and myelomas. TCBs label tumor cells with one of their ends, and attract immune cells with another end to coerce them into tumor cell killing. However, one major challenge in the development of TCBs are “on-target, off-tumor” toxicities at sites in the body that also express TCB-targeted antigens. A new collaboration of Jennifer Lewi...
August 23, 2023
-- Dr. Peterson’s extensive experience includes clinical development, medical affairs, and regulatory leadership in support of innovative oncology product portfolios -- ...
August 22, 2023
Genesis Therapeutics recently joined the growing list of AI-powered drug discovery startups receiving venture funding this year. The company closed a $200 million Series B financing round, taking its total funding to date to more than $280 million.
August 22, 2023
The partners created a registry to generate real-world data using consenting U.S. patients' medical records to further research in stage 1 to 3 breast cancer.
August 22, 2023
Dublin, Aug. 22, 2023 (GLOBE NEWSWIRE) -- The "Global Allogeneic Cell Therapy Market: Distribution by Type of Cell Therapy, Source of Cell, Target...
August 22, 2023
The FDA has granted full approval to Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive NSCLC.
August 22, 2023
/PRNewswire/ -- The "Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS)-inhibitors - Market Insights, Epidemiology and Market Forecast - 2032" report has been...